Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 931-722-2 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The main component of the substance “Reaction product of lead chloride or lead sulphate with alkaline solution” is lead (Pb). Pb salts used as source material are waste materials produced by Pb battery recycling process or by-products of the hydrometallurgical upgrading of PGM rich lead bullion. This transported isolated intermediate is produced under strictly controlled conditions, therefore there is no basis for further hazard assessment. It is an inorganic solid UVCB-substance having ~85% of particles smaller than 400 µm. The major and the most hazardous constituent of this intermediate is lead (conc. >50 %) which is determined to be poorly water soluble (section 4.8, EU method A.6), given that dissolution is widely considered to be required prior to percutaneous absorption, this may be interpreted as a likely indication of low bioavailability via the dermal exposure route.
Studies presented for skin sensitisation were performed with three selected lead compounds on an exemplary basis: lead oxide, dibasic lead phosphite and dibasic lead phthalate (Bien, 2003a,b,c). Rationality for selecting these compounds is exposure within industry, compound with inorganic anion and low solubility and compound with an organic anion with relatively high solubility, respectively. Lead compounds did not exhibit sensitative properties.
The classification is based on the composition of “Reaction product of lead chloride or lead suphate with alkaline solution” (see section 4.23), and assessed by using C&L rules for mixtures. All constituents in this intermediate having classification entries in CLP Annex VI were considered. As a worst-case assumption all relevant compounds are considered leachable i.e. bioavailable. The 100% distribution means that e.g. when 50 % Pb is present that all of it (100%) is allocated to the form of 'Pb compounds' and not a certain amount as e.g. PbCO3, which could result in a different classification.
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in vitro
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- an in vitro skin sensitisation study does not need to be conducted because adequate data from an in vivo skin sensitisation study are available
- Reason / purpose for cross-reference:
- data waiving: supporting information
- Reason / purpose for cross-reference:
- data waiving: supporting information
- Reason / purpose for cross-reference:
- data waiving: supporting information
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- August-December 2003
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study
- Justification for type of information:
- Hypothesis for read-across: Lead (Pb) is the main component of the target substance, and considered the major driver for adverse effects based on its properties and relative quantity in the substance. For toxicity assessment the bioavailable part is relevant. From the target substance itself, Pb is poorly soluble. For read-across purpose, however, data from more soluble compounds was used. Therefore, it is considered that the used read-across data gives worst-case estimate on the adverse effects. Well-documented and corresponded to the requirements of the recommended Annex V Test Guidelines.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 406 (Skin Sensitisation)
- Deviations:
- yes
- Remarks:
- There was one deviation from the study protocol which was concerned with the relative humidity (section 6.2 Husbandry). At some days of the study the relative humidity was higher than 70%.
- GLP compliance:
- yes (incl. QA statement)
- Type of study:
- guinea pig maximisation test
- Justification for non-LLNA method:
- An appropriate guinea pig maximization test is available, which would not justify conducting an additional LLNA due to animal welfare.
- Species:
- guinea pig
- Strain:
- other: pirbright white
- Sex:
- male/female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Charles River Deutschland GmbH
- Age at study initiation:
- Weight at study initiation: males: 459-545 g; females: 416-530 g
- Housing: The guinea pigs were kept in collective housing up to a maximum of 5 animals per cage in a battery of cages, equipped with a paper disposal system.
- Diet (e.g. ad libitum): "2040 Teklad Global Guinea Pig Diet" (pelleted diet, batch no. K080) offered ad libitum.
- Water (e.g. ad libitum): Tap water as for human consumption was continuously available ad libitum via drinking nipples.
- Acclimation period: 19 days (range finding); 22 days (main test)
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 +/- 3 degrees centigrade
- Humidity (%): 37-76%
- Air changes (per hr): 16 times/ hour and filtered adequately
- Photoperiod (hrs dark / hrs light): 12 hours dark/12 hours light with light on at 7:00AM
IN-LIFE DATES: From: To: - Route:
- intradermal and epicutaneous
- Vehicle:
- other: For the intradermal injection, the test article was diluted with aqua ad iniectabilia and Freund's complete adjuvant to a final concentration of 5%. For the dermal application, the solid test article was used as 50% formulation in petrolatum.
- Concentration / amount:
- Intradermal injection- 5% of the test article
Dermal application 50% in petrolatum - Route:
- epicutaneous, occlusive
- Vehicle:
- other: For the intradermal injection, the test article was diluted with aqua ad iniectabilia and Freund's complete adjuvant to a final concentration of 5%. For the dermal application, the solid test article was used as 50% formulation in petrolatum.
- Concentration / amount:
- Intradermal injection- 5% of the test article
Dermal application 50% in petrolatum - No. of animals per dose:
- 10 test and 5 control animals
- Details on study design:
- RANGE FINDING TESTS: The range finding test was performed to determine the concentration of the test article to be used in the main test. For the intradermal injection, the test article was diluted with aqua ad iniectabilia (Delta-Pharma, Pfullingen) and Freund's complete adjuvant (FCA; batch no. 62K8933; SIGMA, Steinheim) to a final concentration of 5.0%. Two animals were employed, skin reactions being recorded 48 and 72 hours after treatment. For the dermal application, the solid test article was used 50% in petrolatum. A closed patch exposure was effected by means of an occlusive bandage using cellulose swabs, Leukosilk and non-irritating tape Elastoplast, which enveloped the whole animal's trunk. Two animals were employed and skin reactions were recorded 48 and 72 hours post applicationem.
MAIN STUDY
A. INDUCTION EXPOSURE
- No. of exposures: 3 injection sites
- Exposure period: Seven days after injection, the injection sites were covered occlusively for 48 hours.
- Test groups: 10
- Control group: 5
- Site: Clipped intracapsular region on either side of the spine.
- Frequency of applications: Three pairs of intradermal injections (0.1 ml)
- Duration: Seven days later, the previous injection sites were covered occlusively for 48 hours with a patch carrying the test article (50%) or, in control animals, the control article petrolatum.
- Concentrations: Test Group: 1) FCA 50% (v/v) diluted in aqua ad iniectabilia, 2) testt article 5% in peanut oil, 3) test article 5% in aqua ad iniectabilia/FCA. Control Group: FCA 50% (v/v) diluted in aqua ad iniectabilia, 2) peanut oil, 3) peanut oil 50% (v/v) diluted in FCA.
B. CHALLENGE EXPOSURE
- No. of exposures: 1
- Day(s) of challenge: Both control and test animals were subjected to a challenge exposure 14 days after the second stage of the induction.
- Exposure period: 24 hours
- Test groups: 10
- Control group: 5
- Site: 5 x 5 cm clipped skin area on each flank
- Concentrations: The test article was applied at the concentration of 50% to the left flank and the control article petrolatum to the right in a volume of 0.5 g using the patch technique described under 6.2.1. In each case, the duration of the exposure was 24 hours under an occlusive dressing.
- Evaluation (hr after challenge): 24 and 48 hours after challenge.
OTHER: - Challenge controls:
- Both control and test animals were subjected to a challenge exposure 14 days after the second stage of the induction. The challenge test was performed on a 5 x 5 cm clipped skin area on each flank. The test article was applied at the concentration of 50% to the left flank and the control article petrolatum to the right in a volume of 0.5 g using the patch technique described under 6.2.1. In each case, the duration of the exposure was 24 hours under an occlusive dressing.
- Positive control substance(s):
- yes
- Remarks:
- Assessed at least every 6 months by use of 25% and 50% "4-aminobenzoic acid ethyl ester (benzocaine)" (OECD406) in vaseline. The last test with acceptable levels of responses to this substance was performed from April 8 to 2 May 2003.
- Positive control results:
- Sensitisation rate (50%) at 24 hours: 70% Sensitisation rate (50%) at 48 hours: 70%
Sensitisation rate (25%) at 24 hours: 30% Sensitisation rate (25%) at 48 hours: 20% - Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- negative control
- Dose level:
- 0%
- No. with + reactions:
- 0
- Total no. in group:
- 5
- Clinical observations:
- No findings were observed in control animals.
- Remarks on result:
- no indication of skin sensitisation
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- positive control
- Dose level:
- 25% in vaseline
- No. with + reactions:
- 3
- Total no. in group:
- 10
- Remarks on result:
- positive indication of skin sensitisation
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- positive control
- Dose level:
- 25% in vaseline
- No. with + reactions:
- 2
- Total no. in group:
- 10
- Remarks on result:
- positive indication of skin sensitisation
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- positive control
- Dose level:
- 50% in vaseline
- No. with + reactions:
- 7
- Total no. in group:
- 10
- Remarks on result:
- positive indication of skin sensitisation
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- positive control
- Dose level:
- 50% in vaseline
- No. with + reactions:
- 7
- Total no. in group:
- 10
- Remarks on result:
- positive indication of skin sensitisation
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 50% in petrolatum
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Remarks on result:
- no indication of skin sensitisation
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- According to the EEC Directive 2001/59/EEC, 6 August 2001 and the Gefahrstoffverordnung (GefStoffV) of 15 november 1999 (BGB1. I, p. 2233), the test article "ALLSTAB LP 3139 dibasic lead phosphite" can be classified as a "non-sensitiser since no allergic responses were observed in test animals after the adjuvant test according to Magnusson & Kligman.
- Executive summary:
The potential skin sensitising properties of the test article "ALLSTAB LP 3139" were assessed in the guinea pig maximisation sensitisation test carried out as an adjuvant test according to the Magnusson & Kligman maximisation test method, using 10 test and 5 control animals in the main test. Following the induction exposure to the test article (50% in petrolatum) or the vehicle petrolatum (control article), the animals of both groups were subjected two weeks later to a challenge exposure with the test article (50% in petrolatum) as well as the control article. Responses to the challenge procedure were evaluated 24 and 48 hours after the end of the exposure period.
Results: No allergic reactions occurred in test animals 24 and 48 hours after the end of the challenge procedure. The sensitisation rate was 0%. No findings were observed in control animals (reaction rate: 0%).
Evaluation: According to nthe EEC Directive 2001/59/EEC, 6 August 2001 and the Gefahrstoffverordnung (GefStoffV) of 15 November 1999 (BGB1. I, p.2233), the test article "ALLSTAB LP 3139 dibasic lead phosphite" can be classified as a "non-sensitiser" since no allergic responses were observed in test animals under the experimental conditions described.
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- August-December 2003
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study
- Justification for type of information:
- Hypothesis for read-across: Lead (Pb) is the main component of the target substance, and considered the major driver for adverse effects based on its properties and relative quantity in the substance. For toxicity assessment the bioavailable part is relevant. From the target substance itself, Pb is poorly soluble. For read-across purpose, however, data from more soluble compounds was used. Therefore, it is considered that the used read-across data gives worst-case estimate on the adverse effects. Well-documented and corresponded to the requirements of the recommended Annex V Test Guidelines.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 406 (Skin Sensitisation)
- Deviations:
- yes
- Remarks:
- Two deviations: No. 1 section 6.1 Animal Specification - Four control animals were used, since one of the male control animals died during the acclimatisation period. No.2: section 6.2 Husbandry - On some days the relative humidity was higher than 70%.
- GLP compliance:
- yes (incl. QA statement)
- Type of study:
- guinea pig maximisation test
- Justification for non-LLNA method:
- An appropriate guinea pig maximization test is available, which would not justify conducting an additional LLNA due to animal welfare.
- Species:
- guinea pig
- Strain:
- other: pirbright white
- Sex:
- male/female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Charles River Deutschland GmbH
- Age at study initiation:
- Weight at study initiation: males 461-492 g; females: 405-484 g
- Housing: The guinea pigs were kept in collective housing up to a maximum of 5 animals per cage in a battery of cages, equipped with a paper disposal system.
- Diet (e.g. ad libitum): 2040 Teklad Global Guinea Pig Diet offerred ad libitum.
- Water (e.g. ad libitum):Tap water as for human consumption was continuously available ad libitum via drinking nipples.
- Acclimation period: 19 days (range finding); 22 days (main test)
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 +/- 3 degrees centigrade. Maximum and minimum temperature and humidity were monitored daily.
- Humidity (%): The relative humidity was kept between 37 and 76%.
- Air changes (per hr): 16 times per hour and filtered adequately.
- Photoperiod (hrs dark / hrs light): 12 hrs dark/ 12 hrs light with light on at 7:00 AM.
IN-LIFE DATES: From: To: - Route:
- intradermal and epicutaneous
- Vehicle:
- other: For the intradermal injection, the test article was diluted with aqua ad iniectabilia and Freund's complete adjuvant to a final concentration of 5%. For the dermal application, the solid test article was used as 50% formulation in petrolatum.
- Concentration / amount:
- Intradermal injection- 5% of the test article
Dermal application 50% in petrolatum - Route:
- epicutaneous, occlusive
- Vehicle:
- other: For the intradermal injection, the test article was diluted with aqua ad iniectabilia and Freund's complete adjuvant to a final concentration of 5%. For the dermal application, the solid test article was used as 50% formulation in petrolatum.
- Concentration / amount:
- Intradermal injection- 5% of the test article
Dermal application 50% in petrolatum - No. of animals per dose:
- 10 test and 4 control animals
- Details on study design:
- RANGE FINDING TESTS: Two animals were employed and skin reactions were recorded 48 and 72 hours post applicationem. For the both the intradermal injection and the dermal application. For the intradermal injection, the test article was diluted with aqua ad iniectabilia and Freund's complete adjuvant to a final concemtration of 5%. Two animals were employed, skin reactions being recorded 48 and 72 hours after treatment. For the dermal application, the solid test article was used as 50% formulation in petrolatum. A closed patch exposure was effected by means of an occlusive bandage using cellulose swabs and non-irritating tape which enveloped the whole animal's trunk.
MAIN STUDY
A. INDUCTION EXPOSURE
- No. of exposures: 3
- Exposure period: Seven days after injections, the injection sites were covered occlusively for 48 hours.
- Test groups: 10
- Control group: 4
- Site: Injections were made in the clipped intracapsular region on either side of the spine
- Frequency of applications: Three pairs of intradermal injections (0.1 ml)
- Duration: Seven days later, the previous injection sites were covered occlusively for 48 hours with a patch carrying the test article (50%) or, in control animals, the control article petrolatum.
- Concentrations: Test Group 1) FCA 50% (v/v) diluted in aqua ad iniectabilia, 2) test article 5% in peanut oil, 3) test article 5% in aqua ad iniectabilia/F CA. Control group: 1) FCA 50% (v/v) diluted in aqua ad iniectabilia, 2) peanut oil, 3) peanut oil 50% (v/v) diluted in FCA.
B. CHALLENGE EXPOSURE
- No. of exposures: 1
- Day(s) of challenge: 14 days after the second stage of the induction
- Exposure period: 24 hours
- Test groups: 10 test animals
- Control group: 4 control animals
- Site: The challenge test was performed on a 5 x 5 cm clipped skin area on each flank.
- Concentrations: The challenge test was applied at the concentration of 50% to the left flank and the control article petroleum to the right in a volume of 0.5 g using the patch tehnique.
- Evaluation (hr after challenge): 24 and 48 hours after patch removal the appearance of the challenge and re-challenge skin sites was observed and skin responses were graffed on the basis of the classification system according DRAIZE. The animals were weighed before treatment and at the end of the study. All findings were recorded with respect to duration and severity on special report forms.
OTHER: - Challenge controls:
- Both control and test animals were subjected to a challenge exposure 14 days after the second stage of the induction. The challenge test was performed on a 5 x 5 cm clipped skin area on each flank. The test article was applied at the concentration of 50% to the left flank and the control article petrolatum to the right in a volume of 0.5 g using the patch technique. In each case, the duration of the exposure was 24 hours under an occlusive dressing.
- Positive control substance(s):
- yes
- Remarks:
- Assessed at least every 6 months by use of 25% and 50% "4-aminobenzoic acid ethyl ester (benzocaine)" (OECD406) in vaseline. The last test with acceptable levels of responses to this substance was performed from April 8 to 2 May 2003.
- Positive control results:
- Sensitisation rate 50% at 24 h: 70% Sensitisation Rate 50% at 48 h: 70%
Sensitisation rate 25% at 24 h: 30% Sensitisation Rate 25% at 48 h: 20% - Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- negative control
- Dose level:
- 0%
- No. with + reactions:
- 0
- Total no. in group:
- 5
- Clinical observations:
- No findings were observed in control animals.
- Remarks on result:
- no indication of skin sensitisation
- Remarks:
- Four control animals were used, since one of the male control animals died during the acclimatisation period.
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- positive control
- Dose level:
- 25% in vaseline
- No. with + reactions:
- 3
- Total no. in group:
- 10
- Remarks on result:
- positive indication of skin sensitisation
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- positive control
- Dose level:
- 25% in vaseline
- No. with + reactions:
- 2
- Total no. in group:
- 10
- Remarks on result:
- positive indication of skin sensitisation
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- positive control
- Dose level:
- 50% in vaseline
- No. with + reactions:
- 7
- Total no. in group:
- 10
- Remarks on result:
- positive indication of skin sensitisation
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- positive control
- Dose level:
- 50% in vaseline
- No. with + reactions:
- 7
- Total no. in group:
- 10
- Remarks on result:
- positive indication of skin sensitisation
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 50% in petrolatum
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- None
- Remarks on result:
- no indication of skin sensitisation
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- According to the EEC Directive 2001/59/EEC, 6 August 2001 and the Gefahrstoffverordnung (GefStoffV) of 15 November 1999 (BGB1. I, p. 2233) testconditions described, the test article "LITHARGE lead oxide" can be classified as a "non-sensitiser" since no allergic responses were observed in test animals under the experimental conditions described.
- Executive summary:
The potential skin sensitising properties of the test article "LITHARGE lead oxide" were assessed in the guinea pig maximisation sensitisation test carried out as an adjuvant test according to the Magnusson & Kligman Maximisation test method, using 10 test and 5 control animals in the main test. Following the induction exposure to the test article (50% in petrolatum) or the vehicle petrolatum (control article), the animals of both groups were subjected two weeks later to a challenge exposure with the test article (50% in petrolatum) as well as the control article. Responses to the challenge procedure were evaluated 24 and 48 hours after the end of the exposure period.
Results: -No allergic skin reactions occurred in test animals 24 and 48 hours after the end of the challenge procedure. The sensitisation rate was 0%
-No findings were observed in control animals (reaction rate:0%).
Evaluation: According to the EEC Directive 2001/59/EEC, 6 August 2001 and the Gefahrstoffverordnung (GefStoffV) of 15 November 1999 (BGB1. I, p.2233) test conditions described, the test article "LITHARGE lead oxide" can be classified as a "non-sensitiser" since no allergic responses were observed in test animals under the experimental conditions described.
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- August-December 2003
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study
- Justification for type of information:
- Hypothesis for read-across: Lead (Pb) is the main component of the target substance, and considered the major driver for adverse effects based on its properties and relative quantity in the substance. For toxicity assessment the bioavailable part is relevant. From the target substance itself, Pb is poorly soluble. For read-across purpose, however, data from more soluble compounds was used. Therefore, it is considered that the used read-across data gives worst-case estimate on the adverse effects. Well-documented and corresponded to the requirements of the recommended Annex V Test Guidelines.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 406 (Skin Sensitisation)
- Deviations:
- yes
- Remarks:
- There was one deviation from the study protocol which was concerned with the relative humidity section 6.2 Husbandry). On some days of the study the relative humidity was higher than 70%.
- GLP compliance:
- yes (incl. QA statement)
- Type of study:
- guinea pig maximisation test
- Justification for non-LLNA method:
- An appropriate guinea pig maximization test is available, which would not justify conducting an additional LLNA due to animal welfare.
- Species:
- guinea pig
- Strain:
- other: pirbright white
- Sex:
- male/female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Charles Rive Deutschland GmbH
- Age at study initiation:
- Weight at study initiation: males: 436-504 g; females: 395-481 g
- Housing: The guinea pigs were kept in collective housing up to a maximum of 5 animals per cage in a battery of cages, equipped with a paper disposal system.
- Diet (e.g. ad libitum): The animals received 2040 Teklad Global Guinea Pig Diet offered ad libitum.
- Water (e.g. ad libitum):Tap water as for human consumption was continuously available ad libitum via drinking nipples.
- Acclimation period: 19 days (range finding); 22 days ( main test)
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 +/-3 degrees centigrade
- Humidity (%): 37-76%
- Air changes (per hr): 16 times per hour and filtered adequately
- Photoperiod (hrs dark / hrs light): 12 hours dark/ 12 hours light with light on at 7:00 AM
IN-LIFE DATES: From: To: - Route:
- intradermal and epicutaneous
- Vehicle:
- other: Intradermal application: The solid test article was diluted with aqua ad iniectabilia and Freund's complete adjuvant to a final concentration of 5%. Dermal Application-the solid test article was used 50% in petrolatum
- Concentration / amount:
- For the intradermal injection, the test article was diluted with aqua ad iniectabilia and Freund's complete adjuvant to a final concentration of 5%. For the dermal application, the solid test article was used 50% in petrolatum.
- Route:
- epicutaneous, occlusive
- Vehicle:
- other: Intradermal application: The solid test article was diluted with aqua ad iniectabilia and Freund's complete adjuvant to a final concentration of 5%. Dermal Application-the solid test article was used 50% in petrolatum
- Concentration / amount:
- For the intradermal injection, the test article was diluted with aqua ad iniectabilia and Freund's complete adjuvant to a final concentration of 5%. For the dermal application, the solid test article was used 50% in petrolatum.
- No. of animals per dose:
- 10 test and 5 control animals
- Details on study design:
- RANGE FINDING TESTS: The range finding test was performed to determine the concentrations of the test article to be used in the main test. For the intradermal injection, the test article was diluted with aqua ad iniectabilia and Freund's complete adjuvant to a final concentration of 5%. Two animals were employed, skin reactions being recorded 48 and 72 hours after treatment. For the dermal application, the solid test article was used 50% in petrolatum. A closed patch exposure was effected by means of an occlusive bandage using swabs, Leukosilk, and non-irritating tape Elastoplast which enveloped the whole animal's trunk. Two animals were employed and skin reactions were recorded 48 and 72 hours post applicationem.
MAIN STUDY
A. INDUCTION EXPOSURE
- No. of exposures: 3
- Exposure period: Seven days after the injection, the injection sites were covered occlusively for 48 hours.
- Test groups: 10 guinea pigs
- Control group: 5 guinea pigs
- Site: Injections were made in the clipped intracapsular region on either side of the spine.
- Frequency of applications: Three pairs of intradermal injections (0.1 ml)
- Duration: Seven days after the injection, the injection sites were covered occlusively for 48 hours with a patch carrying the test article (50%) or, in control animals, the control article petrolatum.
- Concentrations: Test group: 1) FCA 50% (v/v) diluted in aqua ad iniectabilia, 2) test article 5% in peanut oil, 3) test article 5% in aqua iniectabilia/FCA. Control group: 1) FCA 50% (v/v) diluted in aqua ad iniectabilia, 2) peanut oil, 3) peanut oil 50% (v/v) diluted in FCA.
B. CHALLENGE EXPOSURE
- No. of exposures: 1
- Day(s) of challenge: 14 days after the second stage of the induction
- Exposure period: 24 hours
- Test groups: 10 test animals
- Control group: 5 control animals
- Site: The challenge test was performed on a 5 x 5 cm clipped skin area on each flank.
- Concentrations: The test article was applied at the concentration of 50% to the left flank and the control article petrolatum to the right in a volume
of 0.5 g using the patch technique. In each case, the duration of exposure was 24 hours under an occlusive dressing.
- Evaluation (hr after challenge): 24 and 48 hours after patch removal the appearance of the challenge and re-challenge skin sites was observed and skin responses were gradfed on the basis of the classification system according DRAIZE. The animals werer weighed before treatment and at the end of the study. Al findings were recorded with respect to duration and severity on special report forms.
OTHER: - Challenge controls:
- The control article petrolatum was applied to the left flank of the guinea pig in a volume of 0.5 g using the patch technique for 24 hours under an occlusive dressing.
- Positive control substance(s):
- yes
- Remarks:
- Assessed at least every 6 months by use of 25% and 50% "4-aminobenzoic acid ethyl ester (benzocaine)" (OECD406) in vaseline. The last test with acceptable levels of responses to this substance was performed from April 8 to 2 May 2003.
- Positive control results:
- Sensitisation rate (50%) at 24 h: 70% Sensitisation rate (50%) at 48h: 70%
Sensitisation rate (25%) at 24 h: 30% Sensitisation rate (25%) at 24h: 30% - Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- negative control
- Dose level:
- 0%
- No. with + reactions:
- 0
- Total no. in group:
- 5
- Clinical observations:
- No findings were observed in control animals.
- Remarks on result:
- no indication of skin sensitisation
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 50% in petrolatum
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- None
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: test group. Dose level: 50% in petrolatum. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: None.
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- positive control
- Dose level:
- 25% in vaseline
- No. with + reactions:
- 3
- Total no. in group:
- 10
- Remarks on result:
- positive indication of skin sensitisation
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- positive control
- Dose level:
- 25% in vaseline
- No. with + reactions:
- 3
- Total no. in group:
- 10
- Remarks on result:
- positive indication of skin sensitisation
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- positive control
- Dose level:
- 50% in vaseline
- No. with + reactions:
- 7
- Total no. in group:
- 10
- Remarks on result:
- positive indication of skin sensitisation
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- positive control
- Dose level:
- 50% in vaseline
- No. with + reactions:
- 7
- Total no. in group:
- 10
- Remarks on result:
- positive indication of skin sensitisation
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- According to the EEC Directive 2001/59/EEC, 6 August 2001 and the Gefahrstoffverordnung (GefStoffV) of 15 November 1999 (BGB1. I, p. 2233), thetest article PEBETAL dibasic lead phthalate can be classified as a "non-sensitiser" since no allergic responses were observed in test animals after the adjuvant test according to Magnusson & Kligman.
- Executive summary:
The potential skin sensitising properties of the test article PEBETAL dibasic lead phthalate were assessed in the guinea pig maximisation test method, using 10 test and 5 control animals in the main test. Following the induction exposure to the test article (50% in petrolatum) or the vehicle petrolatum (control article), the animals of both groups were subjected two weeks later to a challenge with the test article (50% in petrolatum) as well as the control article. Responses to the challenge procedure were evaluated 24 and 48 h after the end of the exposure period.
Results: - No allergic skin reactions occurred in test animals 24 and 48 h after the end of the challenge procedure. The sensitisation was 0%.
-No findings were observed in control animals (reaction rate: 0%).
According to the EEC Directive 2001/59/EEC, 6 August 2001 and the Gefahrstoffverordnung (GefStoffV) of 15 November 1999 (BGB1 I. p. 2233), the test article PEBETAL dibasic lead phthalate can be classified as a "non-sensitiser" since no allergic responses were observed in test animals under the experimental conditions described.
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- weight of evidence
- Justification for type of information:
- Justification for read-across: Lead (Pb) is the main component of the target substance, and considered the major driver for adverse effects based on its properties and relative quantity in the substance. For toxicity assessment the bioavailable part is relevant. From the target substance itself, Pb is poorly water soluble. For read-across purpose, however, data from more soluble compounds was used. Therefore, it is considered that the used read-across data gives worst-case estimate on the adverse effects.
See IUCLID Section 13 for Analogue approach report. - Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reading:
- other: Read-across conclusion
- Remarks on result:
- no indication of skin sensitisation
- Remarks:
- This conclusion is based on the results of the in vivo studies performed the 3 test articles (Lead monoxide, [phthalato(2-)]dioxotrilead and trilead dioxide phosphonate). The tests with the three latter substances were performed according to non-LLNA methods.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- When administered to the eye, the 3 test articles (Lead monoxide, [phthalato(2-)]dioxotrilead and trilead dioxide phosphonate) are classified as "non sensitizing to the skin".
Based on the similarities between these three test articles and the target substance described in the read-across jsutification inculded in section 13, the target substance is considered to be "non sensitizing to the skin".
Referenceopen allclose all
There were no skin reactions after the dermal application in the induction phase. No allergic skin reactions were observed in test animals after the challenge exposure 24 and 48 hours after patch removal. No findings were observed in control animals.
The sesitisation rate, i.e. the number of animals showing an alergic response expressed as a percentage of the total number of animals, was determined 24 and 48 hours after patch removal and was 0% in test animals in each case. The corresponding reaction rate in control animals was 0%.
Justification for read-across: Lead (Pb) is the main component of the target substance, and considered the major driver for adverse effects based on its properties and relative quantity in the substance. For toxicity assessment the bioavailable part is relevant. From the target substance itself, Pb is poorly water soluble. For read-across purpose, however, data from more soluble compounds was used. Therefore, it is considered that the used read-across data gives worst-case estimate on the adverse effects.
See IUCLID Section 13 for Analogue approach report.
No allergic skin reactions occurred in test animals 24 and 48 hours after the end of the challenge procedure. The sensitisation rate was 0%. No findings were observed in control animals (reaction rate :0%).
Justification for read-across: Lead (Pb) is the main component of the target substance, and considered the major driver for adverse effects based on its properties and relative quantity in the substance. For toxicity assessment the bioavailable part is relevant. From the target substance itself, Pb is poorly water soluble. For read-across purpose, however, data from more soluble compounds was used. Therefore, it is considered that the used read-across data gives worst-case estimate on the adverse effects.
See IUCLID Section 13 for Analogue approach report.
There were no skin reactions after the dermal application in the induction phase. No allergic skin reactions were observed in the test animals after the challenge exposure 24 and 48 h after patch removal. No findings were observed in control animals. The sensitisation rate, i.e. the number of animals showing an allergic response expressed as a percentage of the total number of animals, was determined 24 and 48 h after patch removal and was 0% in test animals in each case. The corresponding reaction rate in control animals was 0%.
Justification for read-across: Lead (Pb) is the main component of the target substance, and considered the major driver for adverse effects based on its properties and relative quantity in the substance. For toxicity assessment the bioavailable part is relevant. From the target substance itself, Pb is poorly water soluble. For read-across purpose, however, data from more soluble compounds was used. Therefore, it is considered that the used read-across data gives worst-case estimate on the adverse effects.
See IUCLID Section 13 for Analogue approach report.
Endpoint conclusion
- Additional information:
Justification for read-across: Lead (Pb) is the main component of the target substance, and considered the major driver for adverse effects based on its properties and relative quantity in the substance. For toxicity assessment the bioavailable part is relevant. From the target substance itself, Pb is poorly water soluble. For read-across purpose, however, data from more soluble compounds was used. Therefore, it is considered that the used read-across data gives worst-case estimate on the adverse effects. See IUCLID Section 13 for Analogue approach report.
Studies (Bien a,b,c 2003) exhibit no sensitisation potential on skin. The lack of toxicity, irritation or reports of sensitisation from occupational exposure settings, do not appear to pose risk of sensitisation and classification for these endpoints is not indicated. Lead and sparingly soluble lead compounds do not raise a concern since
dissolution is widely considered to be required prior to percutaneous absorption, this may be interpreted as a likely indication of low bioavailability via the dermal exposure route.
The classification is based on the composition of “Reaction product of lead chloride or lead suphate with alkaline solution” (see section 4.23), and assessed by using C&L rules for mixtures. All constituents in this intermediate having classification entries in CLP Annex VI were considered. As a worst-case assumption all relevant compounds are considered leachable i.e. bioavailable. The 100% distribution means that e.g. when 50 % Pb is present that all of it (100%) is allocated to the form of 'Pb compounds' and not a certain amount as e.g. PbCO3, which could result in a different classification.
Calculated classification was performed from all constituents in this intermediate having classification entries in CLP Annex VI (using mixture toxicity rules) with MeClas-tool. For sensitisation no major drivers were designated, thus no classification.
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
The derived classification result for the UVCB substance with calculation with C&L mixture rules by Meclas-tool is:
CLP: Not classified for sensitisation properties.
See section 13 "Assessment Reports" for details of MeClas-classification approach.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.